로딩 중…
지수 로딩 중…
Tango Therapeutics Inc.
TNGX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$27.21+0.11%
2026-08-03
Financials
Valuation Metrics
Tango Therapeutics Inc.'s Market Cap is $3.94B. At end of 2025 it was $1.03B. Ranked #1572 of 3,112 in US market (top 51%), #547 of 1,445 on NASDAQ (top 38%), #90 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.94B | US#1,572/3,112 Sec#90/269 |
| Revenue | $57M | US#2,850/3,112 Sec#151/269 |
| Net Income | $-107M | US—/3,112 Sec—/269 |
| Total Assets | $436M | US#2,797/3,112 Sec#174/269 |
| Net Assets | $392M | US#2,419/3,112 Sec#137/269 |
| Value | ||
| P/B | 10.05x | US#2,617/3,112 Sec#205/269 |
| P/S | 69.06x | US#2,893/3,112 Sec#173/269 |
| FCF Yield | -3.62% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -27.39% | US#2,593/3,112 Sec#120/269 |
| ROA | -24.61% | US#2,822/3,112 Sec#142/269 |
| Op. Margin | -206.22% | US#2,862/3,112 Sec#139/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 11.31% | US#125/3,112 Sec#54/269 |
| Total Debt | $33M | US#2,627/3,112 Sec#164/269 |
| FCF | $-143M | US#2,671/3,112 Sec#185/269 |
| Cash | $158M | US#1,904/3,112 Sec#142/269 |
| Current Ratio | 27.38x | US#93/3,112 Sec#14/269 |
| Performance | ||
| 1Y Return | 316.69% | US#45/3,112 Sec#18/269 |
| 1M Return | -7.64% | US#2,458/3,112 Sec#145/269 |
| From 52W High | -20.88% | US#1,767/3,112 Sec#114/269 |
| 1Y MDD | -29.24% | US#1,325/3,112 Sec#83/269 |
| Trading | ||
| Volume | 1,830,590 shares | US#965/3,112 Sec#87/269 |
| Trading Value | $49M | US#1,367/3,112 Sec#86/269 |